G . ST E V E N B OVA
M ost of the damage that cancer does is caused by the spread of cells from the primary cancer site to other regions of the body. These metastatic cancer cells accrue genomic changes beyond those found in the primary tumour, and some such changes allow the metastatic cancer to survive in the face of therapy. Molecular studies of metastatic cancer tissues can provide valuable insights into how this resistance might be overcome, but such studies have been relatively rare, mainly because of logistical and technical barriers. Robinson et al. 1 report on page 297 that they have extended work from earlier studies 2,3 to take detailed snapshots of genome sequences and immune responses in metastatic cancer tissues from 500 people, known as the MET500 cohort.
The authors enrolled patients whose meta stases derived from 30 types of primary cancer (the most common were prostate, breast and soft-tissue-sarcoma metastases), and patients for whom the primary cancer was unknown. Female and male patients of different ethnicities were enrolled from 22 cancer centres across the United States, but most were from the University of Michigan Comprehensive Cancer Center. Tissue samples came from more than 20 organs.
Robinson et al. sequenced the proteincoding portion of the genome from metastatic tissue samples and compared these exome sequences with those from non-cancerous tissue from the same patient. Next, they sequenced messenger RNA from the metastases, and compared this with mRNA profiles from corresponding normal tissues taken from reference databases. Together, these analyses provided information about the genetic mutations and the altered gene-expression profiles that characterize the metastases and their supporting tissues. The analyses complement genomic studies of primary cancers, many of which have been conducted by two large consortia: The Cancer Genome Atlas (http:// cancergenome.nih.gov) and the International Cancer Genome Consortium (http://icgc.org).
For people who have cancer, Robinson and colleagues' work is important on two levels. First, it demonstrates that a set of difficult challenges can be overcome in a clinical setting to biopsy metastatic cancers and obtain integrated exomic and mRNA data sets for each patient. These challenges include: logistical ones, such as obtaining biopsies from regions of the body that are difficult to access; technical challenges (metastasis biopsies are often tiny, and the fraction of tumour cells compared to healthy cells can be low); and ethical challenges for the patient, physician and researchers when assessing the risks and possible value of taking a biopsy -especially because the potential benefit for patients is not well defined.
Second, the work has produced a wealth of publicly available information (http://met500. path.med.umich.edu) that will help to guide future approaches to cancer treatment based on precision medicine. The integrated analysis of each patient's biopsy and matched normal tissue delivers a map of what is going on in each metastasis sampled. The analysis, therefore, provides information about genetic mutations that could potentially be targeted by drugs; about the immune response and other microenvironmental responses to the tumour, which could also point to therapeutic options; and about mutations present in the non-cancerous DNA from each patient, which might indicate the mutations that predispose them to cancer. The latter could have implications not only for the patient's treatment, but also for risk management in the person's family.
Notably, Robinson and colleagues identified mutations in germline DNA (that with which the patient was born) that could confer predisposition to cancer in 12.2% of the MET500 cohort. This striking finding is consistent with previous studies limited to people with metastatic prostate cancer 2 -some of whom may also have been included in the MET500 cohort. Studies involving larger numbers of people with metastasis are now needed to determine whether a diagnosis of metastatic cancer should trigger more-intense evaluation of familial cancer risk than currently occurs.
One of several interesting findings in Robinson and colleagues' study is that metastatic cancers fall into two main subtypes on the basis of their mRNA profiles -one associated with inflammation, and a second, proliferative subtype associated with increased metabolism and systemic stress signalling. If this pattern is found across multiple metastases in individual patients, it seems likely that where the metastatic cancer sits in this spectrum could strongly influence response to specific therapies.
Another finding of interest lies in the analysis of the magnitude of immune-cell infiltration in metastatic cancers (MImmScore 4 ), which is a measure of how the body's immune system is responding to a tumour. This and other immune measures reported in the work could potentially help to select therapies and analyse patient responses in clinical trials of emerging immunotherapies, which modulate the body's immune response to target cancer. The highest average MImmScores were found in kidney cancer and certain cancers of the skin and thymus gland, and the lowest were in testicular cancers and cancers of the adrenal gland. However, each tumour type had outliers that had relatively high or low immune infiltration, and some (including metastatic pancreatic, lung, thyroid and liver cancers) had especially broad ranges of infiltration between people who had those metastatic cancer types.
Robinson and colleagues' study is the largest of its kind. Establishing the potential usefulness of this type of integrated genomic approach to improving cancer management and best practices will require many more well-curated cases, in addition to a record of outcomes, which was not included in the current study. Moreover, metastatic cancers evolve over time [5] [6] [7] [8] [9] [10] and in response to therapy 11, 12 -it remains to be seen when and how often biopsies should be taken, and which of the various types of sequencing analysis are essential, for this type of approach to best help clinicians select therapies. Could tumour-derived molecules circulating in the blood be used instead of a biopsy in some circumstances 13 , and if so, which ones? Further analysis of the MET500 cohort, alongside future reports from similar cohorts, will help to resolve these issues.
Because of its broad focus and deep analysis, Robinson and co-workers' study advances our knowledge of shared and distinct mutations, shared patterns of mRNA expression and shared immune responses between metastatic cancer types. This knowledge should help researchers to prioritize their efforts to develop effective treatments. ■ 
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tars that have more than about nine times the mass of our Sun lose considerable mass throughout their lifetimes as a result of stellar winds, a process that provides elements for the next generation of stars and for planet formation. On page 310, Ohnaka et al.
1 present the first two-dimensional map to depict the velocity of gas across the surface of a red supergiant -a massive star at a late stage of its evolution. The map shows large clumps of upwelling and downdraughting gas in the star's outer atmosphere, and suggests that convection alone cannot be responsible for lifting material away from the stellar surface of massive stars as had been thought.
Ohnaka and colleagues studied Antares, the brightest star in the constellation of Scorpius (Fig. 1) . It is known as the heart of the scorpion because of its red colour and location in the body of the beast depicted by the constellation. Antares has a mass about 15 times that of the Sun and is nearing the end of its life. It has therefore evolved into a red supergiant, the outer layers of which have expanded 2 outward to a radius of 3.2 astronomical units (1 au corresponds to the average distance between Earth and the Sun). If Antares were at the centre of our Solar System, its outer layers would extend well past the orbit of Mars. It is one of the nearest red supergiants, making the star's apparent size one of the largest as viewed from Earth.
Supergiant stars have large hotspots on their surfaces 3 . Moreover, their atmospheres are complex: some regions extend two to three times beyond the stellar radius and contain clumps of hot atomic gas (detected through ultraviolet emissions 4 ) that coexist with much cooler molecular gas (detected from its radio 5 and near-infrared emissions 2 ). Farther out, supergiant stars are often surrounded by large envelopes of dust 6 that can extend to distances of more than 100 au.
A common explanation for these features is that large convection cells -volumes of mater ial that move as a result of convection -lift gas away from the stellar surface 7 . As material moves away, dust can form in the cooler outer layers, and is subsequently blown farther out through pressure exerted by the star's electromagnetic radiation 6 . This outflow then carries gas away through a process known as viscous drag. However, testing this hypothesis in more detail requires techniques that can measure the motion of gas in the atmospheric layers above the stellar surface at high spatial resolution.
Obtaining such resolution for stars other than the Sun is challenging: Antares is 170 parsecs (550 light years) from Earth 8 , and its diameter subtends an angle of only 37.6 milli arcseconds on the sky. Ohnaka et al. overcame this problem by using the Very Large Telescope Interferometer at the European Southern Observatory in Chile. More specifically, they used an instrument called
ASTRONOMY
A turbulent stellar atmosphere in full view
The dynamic motion of gas in the outer atmosphere of a red supergiant star has been mapped, providing clues to the mysterious mechanism that causes massive stars to lose mass through stellar winds. See Letter p.310 1 present the first 2D map showing the velocity of gas across the surface of Antares, revealing turbulent motions of gas in its atmosphere.
